IDEAYA Biosciences, Inc. IDYA
32.72 USD +0.97 (+3.04%)
At closeNov 11, 2026, 4:01 PM EST
32.72 0.00 0.00%
After hours · Nov 11, 4:01 PM ET
31.35 Day range 32.91
26.81 52-week range 42.68
- YTD
- -5.37%
- 1 year
- +2.20%
News
benzinga.com Mizuho Maintains Outperform on IDEAYA Biosciences, Lowers Price Target to $39 Mizuho analyst Graig Suvannavejh maintains IDEAYA Biosciences (NASDAQ:IDYA) with a Outperform and lowers the price target from $44 to $39.
benzinga.com Citigroup Maintains Buy on IDEAYA Biosciences, Raises Price Target to $66 Citigroup analyst Yigal Nochomovitz maintains IDEAYA Biosciences (NASDAQ:IDYA) with a Buy and raises the price target from $65 to $66.- benzinga.com RBC Capital Maintains Outperform on IDEAYA Biosciences, Lowers Price Target to $45 RBC Capital analyst Leonid Timashev maintains IDEAYA Biosciences (NASDAQ:IDYA) with a Outperform and lowers the price target from $48 to $45.
benzinga.com Truist Securities Reiterates Buy on IDEAYA Biosciences, Lowers Price Target to $57 Truist Securities analyst Gregory Renza reiterates IDEAYA Biosciences (NASDAQ:IDYA) with a Buy and lowers the price target from $59 to $57.
benzinga.com Guggenheim Maintains Buy on IDEAYA Biosciences, Lowers Price Target to $52 Guggenheim analyst Paul Jeng maintains IDEAYA Biosciences (NASDAQ:IDYA) with a Buy and lowers the price target from $57 to $52.
benzinga.com Wedbush Maintains Outperform on IDEAYA Biosciences, Raises Price Target to $63 Wedbush analyst Robert Driscoll maintains IDEAYA Biosciences (NASDAQ:IDYA) with a Outperform and raises the price target from $60 to $63.
prnewswire.com IDEAYA Biosciences to Participate in Upcoming November 2026 Investor Relations Events SOUTH SAN FRANCISCO, Calif., Nov. 4, 2026 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted…
zacks.com IDEAYA Biosciences, Inc. (IDYA) Reports Q3 Loss, Tops Revenue Estimates IDEAYA Biosciences, Inc. (IDYA) came out with a quarterly loss of $1.22 per share versus the Zacks Consensus Estimate of a loss of $1.26. This compares to earnings of $1.33 per share a year ago.- benzinga.com IDEAYA Biosciences Q3 EPS $(1.22) Misses $(1.18) Estimate, Sales $10.242M Beat $6.857M Estimate IDEAYA Biosciences (NASDAQ:IDYA) reported quarterly losses of $(1.22) per share which missed the analyst consensus estimate of $(1.18) by 4.27 percent. This is a 191.73 percent decrease over earnings…
prnewswire.com IDEAYA Biosciences Reports Financial Results for the Third Quarter 2026 and Provides a Business Update Data presented at ESMO 2026 collectively supports the potential of darovasertib to become a foundational new therapy across the treatment journey of uveal melanoma in both primary and metastatic…
prnewswire.com IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) SOUTH SAN FRANCISCO, Calif., Oct. 30, 2026 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery, development and commercialization…
zacks.com IDEAYA Biosciences, Inc. (IDYA) Expected to Beat Earnings Estimates: Can the Stock Move Higher? IDEAYA Biosciences (IDYA) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
defenseworld.net IDEAYA Biosciences (NASDAQ:IDYA) Shares Cross Below 200 Day Moving Average – Should You Sell? IDEAYA Biosciences, Inc. (NASDAQ: IDYA - Get Free Report)'s share price crossed below its 200-day moving average during trading on Monday. The stock has a 200-day moving average of $34.19 and traded…
prnewswire.com IDE849 (SHR-4849) DLL3 TOP1 ADC Updated Phase 1 Results at ESMO 2026 Demonstrates Promising Anti-Tumor Activity and Preliminary Overall Survival Results in Relapsed Small Cell Lung Cancer and Neuroendocrine Carcinomas 17.4-month median OS in 2L SCLC (n=51) and 14.7-month median OS in 2L + ≥3L SCLC (n=101) 72.5% (37/51) ORR and 60.8% (31/51) cORR in 2L SCLC with 6.9-month median PFS; 68.3% (69/101) ORR and 54.5%…
benzinga.com IDEAYA to Present Updated Melanoma Drug Data at Upcoming ESMO Congress IDEAYA Biosciences, Inc. (NASDAQ:IDYA), a leading precision medicine oncology company, today announced updated clinical data from three ongoing studies evaluating darovasertib in metastatic and…
prnewswire.com IDEAYA Biosciences and Servier Announce Data From Three Clinical Trials at ESMO 2026 Supporting the Potential of Darovasertib to Become a Foundational New Therapy for Patients Across the Treatment Journey of Uveal Melanoma OptimUM-01 and OptimUM-02 data supports the broad potential of darovasertib plus crizotinib to drive meaningful clinical benefits for patients with metastatic uveal melanoma, irrespective of…- benzinga.com William Blair Initiates Coverage On IDEAYA Biosciences with Outperform Rating William Blair analyst Alethia Young initiates coverage on IDEAYA Biosciences (NASDAQ:IDYA) with a Outperform rating.
defenseworld.net IDEAYA Biosciences (NASDAQ:IDYA) CEO Sells $985,304.58 in Stock IDEAYA Biosciences, Inc. (NASDAQ: IDYA - Get Free Report) CEO Yujiro Hata sold 26,338 shares of IDEAYA Biosciences stock in a transaction that occurred on Tuesday, October 6th. The shares were sold…
defenseworld.net IDEAYA Biosciences (NASDAQ:IDYA) Stock Jumps 4.8% – Here’s What Happened IDEAYA Biosciences, Inc. (NASDAQ: IDYA - Get Free Report)'s stock price traded up 4.8% on Monday. The company traded as high as $38.38 and last traded at $38.45. Approximately 278,808 shares traded…
prnewswire.com IDEAYA Biosciences Announces the Promotion of Dr. Michael White to President, Research and Development SOUTH SAN FRANCISCO, Calif., Sept. 28, 2026 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted…
prnewswire.com IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) SOUTH SAN FRANCISCO, Calif., Sept. 25, 2026 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted…
defenseworld.net Squarepoint Ops LLC Has $940,000 Holdings in IDEAYA Biosciences, Inc. $IDYA Squarepoint Ops LLC reduced its holdings in IDEAYA Biosciences, Inc. (NASDAQ: IDYA) by 74.6% during the undefined quarter, according to its most recent disclosure with the Securities and Exchange…
seekingalpha.com IDEAYA Biosciences, Inc. (IDYA) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript IDEAYA Biosciences, Inc. (IDYA) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript- benzinga.com Guggenheim Maintains Buy on IDEAYA Biosciences, Raises Price Target to $57 Guggenheim analyst Paul Jeng maintains IDEAYA Biosciences (NASDAQ:IDYA) with a Buy and raises the price target from $54 to $57.
- benzinga.com IDEAYA Biosciences Announced First Patient Has Been Dosed In The OptimUM-11 Phase 3 Registrational Trial Evaluating Darovasertib In Combination With Crizotinib For Patients With Primary Uveal Melanoma Global Phase 3 registrational trial evaluating darovasertib, a first-in-class oral protein kinase C (PKC) inhibitor, in combination with crizotinib, an oral cMET inhibitor, as adjuvant therapy for…
prnewswire.com IDEAYA Biosciences and Servier Announce First Patient Dosed in OptimUM-11 Global Phase 3 Registrational Trial of Darovasertib and Crizotinib as Adjuvant Therapy for Subjects with Uveal Melanoma Global Phase 3 trial will evaluate the darovasertib and crizotinib combination in primary uveal melanoma patients with increased risk of metastasis following completion of local therapy OptimUM-11…- benzinga.com Citizens Reiterates Market Outperform on IDEAYA Biosciences, Maintains $42 Price Target Citizens analyst Silvan Turkcan reiterates IDEAYA Biosciences (NASDAQ:IDYA) with a Market Outperform and maintains $42 price target.
- benzinga.com IDEAYA Sets November R&D Day To Share New Pancreatic Cancer Research And Strategy IDEAYA Biosciences, Inc. (NASDAQ:IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, today announced its upcoming Investor R&D Day in…
prnewswire.com IDEAYA Biosciences Announces London Investor R&D Day and Participation in Upcoming September 2026 Investor Conferences SOUTH SAN FRANCISCO, Calif., Sept. 1, 2026 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted…
benzinga.com IDEAYA Reaches FDA Agreement On Late-Stage Trial Plan For Lung Cancer Drug, Plans Phase 3 Lung Cancer Study For IDE849 By Year-End 2026 IDEAYA Biosciences, Inc. (NASDAQ:IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, announced a successful FDA Type C meeting to…
prnewswire.com IDEAYA Biosciences Announces Successful FDA Type C Meeting for IDE849, DLL3 TOP1 ADC, on Phase 3 Registrational Trial Design for Potential Accelerated and Full Approval in Extensive Stage Small Cell Lung Cancer Based on FDA Type C meeting, targeting to initiate a randomized Phase 3 registrational trial for IDE849 monotherapy by year-end 2026 in ES-SCLC, with ORR by BICR as the primary endpoint for potential…
gurufocus.com IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) PR Newswire SOUTH SAN FRANCISC
prnewswire.com IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) SOUTH SAN FRANCISCO, Calif., Aug. 28, 2026 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted…
seekingalpha.com Ideaya Biosciences: Darovasertib De-Risks A Self-Reinforcing Oncology Platform IDEAYA Biosciences is transitioning into a commercial oncology platform, leveraging darovasertib's registrational success and a robust internal pipeline. Darovasertib's phase 2 trial showed a median…- benzinga.com IDEAYA Biosciences Enters Clinical Collaboration With Roche's Genentech To Evaluate The Efficacy And Safety Of IDE892, Its Investigational MTA-Cooperative PRMT5 Inhibitor, In Combination With GDC-7035, Genentech's KRAS G12D Inhibitor, In Patients With Pancreatic Ductal Adenocarcinoma Collaboration to to evaluate the efficacy and safety of IDE892, its investigational, potential best-in-class MTA-cooperative PRMT5 inhibitor, in combination with GDC-7035 (RG6620), Genentech's KRAS…
benzinga.com Truist Securities Maintains Buy on IDEAYA Biosciences, Lowers Price Target to $59 Truist Securities analyst Gregory Renza maintains IDEAYA Biosciences (NASDAQ:IDYA) with a Buy and lowers the price target from $63 to $59.- benzinga.com Wedbush Maintains Outperform on IDEAYA Biosciences, Raises Price Target to $60 Wedbush analyst Robert Driscoll maintains IDEAYA Biosciences (NASDAQ:IDYA) with a Outperform and raises the price target from $58 to $60.
benzinga.com IDEAYA Biosciences Q2 EPS $(1.22) Misses $(1.09) Estimate, Sales $8.857M Beat $5.015M Estimate IDEAYA Biosciences (NASDAQ:IDYA) reported quarterly losses of $(1.22) per share which missed the analyst consensus estimate of $(1.09) by 11.93 percent. This is a 38.64 percent decrease over losses…- benzinga.com Ideaya Biosciences Initiated Part 2 Monotherapy Expansion In Its Phase 1/2 Trial Of IDE892 In Mtap-Deleted Solid Tumors, With A Focus On Non-small Cell Lung Cancer And Pancreatic Ductal Adenocarcinoma IDE892 is a potential best-in-class PRMT5 inhibitor with 1,400-fold selective MTA-PRMT5 cooperative binding vs SAM-PRMT5 cooperative binding, and CYP3A4 IC50 greater than 45 micromolar with no…
- benzinga.com IDEAYA Biosciences Announces Presentations At 2026 European Society of Medical Oncology Meeting October 23-27, Providing Updates Across IDEAYA's Clinical Pipeline IDEAYA Presentations:2092P (Poster Presentation); Neoadjuvant Darovasertib in Primary Uveal Melanoma: Follow-Up Data from the Phase 2 OptimUM-09 Study. Presenting Author - Mark Shackleton, MBBS, PhD,…
- benzinga.com RBC Capital Maintains Outperform on IDEAYA Biosciences, Lowers Price Target to $48 RBC Capital analyst Leonid Timashev maintains IDEAYA Biosciences (NASDAQ:IDYA) with a Outperform and lowers the price target from $53 to $48.
- benzinga.com Truist Securities Maintains Buy on IDEAYA Biosciences, Lowers Price Target to $63 Truist Securities analyst Gregory Renza maintains IDEAYA Biosciences (NASDAQ:IDYA) with a Buy and lowers the price target from $65 to $63.
benzinga.com Ideaya Biosciences Enrolls First Patient In Its Phase 1 Trial Of IDE892 In Combination With IDE397 In Mtap-deleted Pancreatic And Lung Cancers IDE892 is a potential best-in-class MTA-Cooperative PRMT5 combination partner with MAT2A and pan-RAS inhibitors, with favorable drug-like propertiesIDE892 has a CYP3A4 IC50 greater than 45…- benzinga.com Wedbush Reiterates Outperform on IDEAYA Biosciences, Maintains $58 Price Target Wedbush analyst Robert Driscoll reiterates IDEAYA Biosciences (NASDAQ:IDYA) with a Outperform and maintains $58 price target.
benzinga.com Mission Produce Posts Downbeat Q2 Earnings, Joins Ideaya Biosciences, Perrigo And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session U.S. stock futures higher, Nasdaq up 200 points. Mission Produce (NASDAQ: AVO) shares down on weak earnings. Other stocks also down in pre-market.
benzinga.com Why Nuvalent Shares Are Trading Higher By 38%; Here Are 20 Stocks Moving Premarket GSK to acquire Nuvalent for $10.6 billion, shares rise 38.2%. Other gainers include CCTG, CHAI, RGNT, MTEN, NCRA, ZTG, EPSM, DBI, APLD. Losers include BYAH, NOTV.
benzinga.com 12 Health Care Stocks Moving In Monday's After-Market Session - benzinga.com IDEAYA Biosciences Plans To Commence $300M Common Stock Offering IDEAYA Biosciences, Inc. (NASDAQ:IDYA) today announced that it intends to offer and sell up to $300.0 million of shares of its common stock and, in lieu of common stock, to offer and sell to certain…
- benzinga.com IDEAYA Enters Collaboration With Roche To Evaluate The Efficacy And Safety Of IDE892, Its Investigational PRMT5 Inhibitor, With Roche's RG6505 IDEAYA entered into a clinical collaboration with Roche to evaluate IDE892, IDEAYA's potential best-in-class Phase 1 MTA-cooperative PRMT5 inhibitor, in combination with RG6505, Roche's Phase 1…
- benzinga.com Wedbush Reiterates Outperform on IDEAYA Biosciences, Maintains $58 Price Target Wedbush analyst Robert Driscoll reiterates IDEAYA Biosciences (NASDAQ:IDYA) with a Outperform and maintains $58 price target.